Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8667639 | 1.00 | CA2 (0.69) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL5793343 | 1.00 | CA2 (0.69) | CA2CA1PTPN1CTSLACE | |
| Alcohol SCHEMBL19231109 | 0.94 | CTSL (0.65) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL3497780 | 0.94 | PTPN1 (0.72) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL8520566 | 0.94 | PTPN1 (0.72) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4054766 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4054764 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL8671997 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL13669589 | 0.93 | CTSL (0.67) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4369236 | 0.93 | CTSL (0.67) | CA2CA1PTPN1CTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111432662-B | Pea protein hydrolysate | 嘉吉公司 | 2024-03-19 | — | — | CN | claimed |
| CN-109324128-A | A kind of metabolism group detects general quality-control product and its quality control method | 嘉兴迈维代谢生物科技有限公司 | 2019-02-12 | — | — | CN | claimed |
| CN-102659619-A | Method for synthesis of tyrosine derivative | SHANGHAI JUNJIE BIOCHEMICAL TECHNOLOGY CO LTD | 2012-09-12 | — | — | CN | claimed |
| WO-2006017619-A2 | RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2006-02-09 | — | — | US | claimed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| CN-120309503-A | Synthesis method of intermediate for preparing hydrochloric acid Luo Xianan | 山西千岫制药有限公司 | 2025-07-15 | — | — | CN | disclosed |
| CN-113163799-B | Corn protein hydrolysate and preparation method thereof | 嘉吉公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-115850107-B | Industrial synthesis method of hydrochloric acid Luo Xianan | 苏州诚和医药化学有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-116004423-B | Bacillus bailii and application thereof | 大连工业大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-116064280-B | Siamese bacillus and application thereof | 大连工业大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-111432662-B | Pea protein hydrolysate | 嘉吉公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116888138-A | Radiopharmaceutical conjugate compositions and uses thereof | 瑞择生物公司 | 2023-10-13 | — | — | CN | disclosed |
| US-4800162-A | ENZYME-ACTIVATED MEMBRANE | SEPRACOR, INC. (US) | 1989-01-24 | — | — | US | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0136728-B1 | PROCESS FOR THE DISSOLUTION OF PEPTIDES AND PROTEINS, SOLUTIONS THEREBY OBTAINED AND THEIR USE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-05-06 | — | — | EP | disclosed |
| EP-0009898-B1 | NOVEL ANTI-HYPERTENSIVE MERCAPTOACYLAMINO ACID DERIVATIVES, THEIR PREPARATION AND USE | UNIVERSITY OF MIAMI (US) | 1983-05-18 | — | — | EP | disclosed |
| US-3855062-A | PROCESS FOR PREPARATION OF DERIVATIVES OF L-TYROSINE | BOEHRINGER SOHN INGELHEIM | 1974-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | ITGB3, ITGB5, ITGA5 | CA2 2656/4885CA1 1817/4885PTPN1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.